Who are Inqovi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DAC, Consolidation, III HiDAraC cycle, II Consolidation HiDAraC, LoDAC, CEDAZURIDINE, Dacogen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inqovi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Inqovi — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inqovi (Inqovi) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Metabolic Inhibitor [EPC]. Area: Oncology.

marketed Nucleoside Metabolic Inhibitor [EPC] Cytidine deaminase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Inqovi — Otsuka. Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inqovi TARGET	Inqovi	Otsuka	marketed	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	2020-01-01
DAC	DAC	dr hab. n. med. Agnieszka Wierzbowska	marketed	Cytidine deaminase inhibitor	Cytidine deaminase
Consolidation, III HiDAraC cycle	Consolidation, III HiDAraC cycle	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA/RNA synthesis (cytidine deaminase inhibition pathway)
II Consolidation HiDAraC	II Consolidation HiDAraC	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA synthesis (cytidine deaminase inhibition pathway)
LoDAC	LoDAC	Sunshine Lake Pharma Co., Ltd.	phase 3	Nucleoside analog / Antimetabolite	DNA synthesis (cytidine deaminase inhibition pathway)
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-16 — Inqovi · 8618075 · US
2028-10-16 — Inqovi · 9567363 · US
2030-08-22 — Inqovi · 8268800 · US

Sponsor landscape (Nucleoside Metabolic Inhibitor [EPC] class)

· 4 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Cheplapharm · 1 drug in this class
Extrovis · 1 drug in this class
Hospira Inc · 1 drug in this class
Novartis · 1 drug in this class
Otsuka · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sanofi · 1 drug in this class
Sun Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inqovi — Competitive Intelligence Brief. https://druglandscape.com/ci/inqovi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing